PT3121266T - Meios de cultura celulares livres de oligopeptídeos - Google Patents

Meios de cultura celulares livres de oligopeptídeos

Info

Publication number
PT3121266T
PT3121266T PT161839873T PT16183987T PT3121266T PT 3121266 T PT3121266 T PT 3121266T PT 161839873 T PT161839873 T PT 161839873T PT 16183987 T PT16183987 T PT 16183987T PT 3121266 T PT3121266 T PT 3121266T
Authority
PT
Portugal
Prior art keywords
oligopeptide
cell culture
culture media
free cell
free
Prior art date
Application number
PT161839873T
Other languages
English (en)
Original Assignee
Baxalta Inc
Baxalta GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37942126&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3121266(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxalta Inc, Baxalta GmbH filed Critical Baxalta Inc
Publication of PT3121266T publication Critical patent/PT3121266T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/005—Protein-free medium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/46—Amines, e.g. putrescine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/50—Soluble polymers, e.g. polyethyleneglycol [PEG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
PT161839873T 2006-01-04 2007-01-03 Meios de cultura celulares livres de oligopeptídeos PT3121266T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75641906P 2006-01-04 2006-01-04

Publications (1)

Publication Number Publication Date
PT3121266T true PT3121266T (pt) 2020-05-19

Family

ID=37942126

Family Applications (3)

Application Number Title Priority Date Filing Date
PT161839873T PT3121266T (pt) 2006-01-04 2007-01-03 Meios de cultura celulares livres de oligopeptídeos
PT77025740T PT1974014T (pt) 2006-01-04 2007-01-03 Meios de cultura celulares livres de oligopeptídeos
PT121607899T PT2522717E (pt) 2006-01-04 2007-01-03 Meios de cultura celulares livres de oligopeptídeos

Family Applications After (2)

Application Number Title Priority Date Filing Date
PT77025740T PT1974014T (pt) 2006-01-04 2007-01-03 Meios de cultura celulares livres de oligopeptídeos
PT121607899T PT2522717E (pt) 2006-01-04 2007-01-03 Meios de cultura celulares livres de oligopeptídeos

Country Status (18)

Country Link
US (4) US20070212770A1 (pt)
EP (4) EP3653699A1 (pt)
JP (6) JP5259418B2 (pt)
KR (2) KR101422435B1 (pt)
CN (2) CN102643777A (pt)
AU (1) AU2007204044B2 (pt)
CA (1) CA2633306A1 (pt)
CY (1) CY1119046T1 (pt)
DK (3) DK1974014T3 (pt)
ES (3) ES2474573T3 (pt)
HK (1) HK1177950A1 (pt)
HU (1) HUE032744T2 (pt)
LT (1) LT1974014T (pt)
PL (3) PL3121266T3 (pt)
PT (3) PT3121266T (pt)
RU (3) RU2486236C2 (pt)
SI (1) SI2522717T1 (pt)
WO (1) WO2007077217A2 (pt)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2486236C2 (ru) 2006-01-04 2013-06-27 Бакстер Интернэшнл Инк. Способ экспрессии белка
ES2644089T3 (es) 2007-12-27 2017-11-27 Baxalta GmbH Procedimientos de cultivo celular
CN101910401A (zh) * 2007-12-31 2010-12-08 巴克斯特国际公司 基本上无动物蛋白的重组体弗林蛋白酶及其生产方法
US8637312B2 (en) 2008-01-09 2014-01-28 Cellca Gmbh Mammalian culture media with polyamine and iron
AU2009244776B2 (en) * 2008-02-25 2013-03-07 Nanotherapeutics, Inc. Method for producing continuous cell lines
EP2977461A1 (en) * 2008-11-12 2016-01-27 Baxalta Incorporated Method of producing serum-free insulin-free factor vii
KR101756354B1 (ko) 2009-07-31 2017-07-26 백스터 인터내셔널 인코포레이티드 Ａｄａｍｔｓ 단백질 발현을 위한 세포 배양 배지
US8580554B2 (en) * 2009-07-31 2013-11-12 Baxter International Inc. Method of producing a polypeptide or virus of interest in a continuous cell culture
KR20220139456A (ko) 2009-09-21 2022-10-14 다케다 야쿠힌 고교 가부시키가이샤 안정화된 액체 및 동결건조된 ａｄａｍｔｓ13 제제
CA2797140C (en) 2010-04-26 2018-01-23 Novartis Ag Improved cell culture medium
PL2591094T3 (pl) 2010-07-08 2019-02-28 Baxalta GmbH Sposób otrzymywania rekombinowanego adamts13 w linii komórkowej
PL2616090T3 (pl) 2010-09-17 2023-12-18 Takeda Pharmaceutical Company Limited Stabilizowanie immunoglobulin poprzez wodną formulację z histydyną o ph od słabo kwaśnego do obojętnego
TW201708251A (zh) 2010-10-27 2017-03-01 巴克斯歐塔公司 用於免疫耐受誘導及免疫診斷之ｆｖｉｉｉ胜肽
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
PT3412305T (pt) 2011-06-10 2021-01-29 Baxalta Inc Tratamento de doença da coagulação através da administração de vwf recombinante
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
EP2906683B1 (en) 2012-10-15 2017-05-31 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
AR095196A1 (es) * 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
KR101641655B1 (ko) * 2014-01-08 2016-07-21 서울대학교산학협력단 스퍼미딘 또는 스퍼민을 이용함으로써 생육 저해제에 대한 내성이 증진된 효모의 배양방법
US10221124B2 (en) * 2015-03-17 2019-03-05 Dsm Ip Assets B.V. Process for the preparation of diaminobutane
TWI797060B (zh) 2015-08-04 2023-04-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
WO2017093482A1 (en) 2015-12-02 2017-06-08 Csl Behring Recombinant Facility Ag Improved media for the expression of recombinant vitamin k-dependent proteins
CN106635953B (zh) * 2016-12-13 2021-02-19 昆明润什生物科技有限公司 无血清无蛋白细胞培养基
KR20210084695A (ko) * 2017-07-06 2021-07-07 리제너론 파마슈티칼스 인코포레이티드 당단백질을 만들기 위한 세포 배양 과정
KR20200037251A (ko) 2017-07-07 2020-04-08 박스알타 인코퍼레이티드 재조합 vwf의 투여에 의해 대기 수술을 받은 중증 폰 빌레브란트 병을 가지고 있는 환자의 치료
CN111436193A (zh) 2017-07-07 2020-07-21 百深公司 通过施用重组vwf来治疗患有严重冯维勒布兰德病的患者中的胃肠道出血
AU2019240135A1 (en) 2018-03-21 2020-10-22 Takeda Pharmaceutical Company Limited Separation of VWF and VWF propeptide by chromatographic methods
CN112313511A (zh) 2018-04-20 2021-02-02 詹森生物科技公司 用于制备抗il12/il23抗体组合物的制造方法中的色谱柱鉴定
CN108872758B (zh) * 2018-05-10 2019-06-28 江苏大学 一种电子元器件寿命检测装置
AU2019379858B2 (en) 2018-11-13 2024-01-04 Janssen Biotech, Inc. Control of trace metals during production of anti-CD38 antibodies
EA202192140A1 (ru) 2019-02-01 2021-12-15 Такеда Фармасьютикал Компани Лимитед СПОСОБЫ ПРОФИЛАКТИЧЕСКОГО ЛЕЧЕНИЯ РЕКОМБИНАНТНЫМ ФВ (рФВ)
JP2022525145A (ja) 2019-03-14 2022-05-11 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ１２／ｉｌ２３抗体組成物を生成するための製造方法
CN113840838A (zh) 2019-03-14 2021-12-24 詹森生物科技公司 用于产生抗tnf抗体组合物的制造方法
EP3947632A1 (en) 2019-04-01 2022-02-09 The Automation Partnership (Cambridge) Ltd. Operation process for a cell cultivation system
JP2022547556A (ja) 2019-09-11 2022-11-14 武田薬品工業株式会社 フォン・ヴィレブランド因子と補体ｃ１ｑの複合体に関連する治療法
KR20220097421A (ko) 2019-11-05 2022-07-07 아지노모토 가부시키가이샤 단백질의 제조 방법
BR112021025769A2 (pt) 2019-12-06 2022-04-12 Regeneron Pharma Composições de proteína anti-vegf e métodos para a produção das mesmas
AR121268A1 (es) 2020-02-04 2022-05-04 Takeda Pharmaceuticals Co Tratamiento de la menorragia en pacientes con enfermedad de von willebrand grave mediante la administración de vwf recombinante
EP4127158A2 (en) 2020-04-02 2023-02-08 Takeda Pharmaceutical Company Limited Adamts13 variant, compositions, and uses thereof
TW202233827A (zh) 2021-01-20 2022-09-01 美商再生元醫藥公司 改良細胞培養中蛋白質效價的方法
CN113151183A (zh) * 2021-04-21 2021-07-23 赵峻岭 一种促进蛋白表达的培养基添加物及其应用
US20230042465A1 (en) 2021-07-09 2023-02-09 Janssen Biotech, Inc. Manufacturing Methods for Producing Anti-TNF Antibody Compositions
AU2022306973A1 (en) 2021-07-09 2024-02-22 Janssen Biotech, Inc. Manufacturing methods for producing anti-il12/il23 antibody compositions
US20230332201A1 (en) 2022-03-02 2023-10-19 Regeneron Pharmaceuticals, Inc. Cell culture methods for antibody production

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT165999B (de) 1947-06-26 1950-05-25 Delle Atel Const Electr Einirchtung zum Schutz von Drehstrommotoren gegen Überstrom
US4443540A (en) * 1980-05-09 1984-04-17 University Of Illinois Foundation Protein hydrolysis
DK207980A (da) * 1980-05-13 1981-11-14 Novo Industri As Fremgangsmaade til fremstilling af et skumnings- eller emulgeringsmiddel paa sojaproteinbasis
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
FR2543158B1 (fr) 1983-03-24 1985-11-15 Inst Nat Sante Rech Med Milieu de culture de cellules animales sans serum, sans hormones et sans facteurs de croissance et procedes de culture primaire et d'obtention de lignees cellulaires utilisant ce milieu
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
IL74909A (en) 1984-04-20 1992-01-15 Genentech Inc Preparation of functional human factor viii and dna sequences,expression vectors,transformed microorganisms and cell lines used therein
EP0217822B1 (en) 1985-02-13 1993-05-12 Scios Nova Inc. Human metallothionein-ii promoter in mammalian expression system
US4978616A (en) * 1985-02-28 1990-12-18 Verax Corporation Fluidized cell cultivation process
DE3787805T2 (de) 1986-08-04 1994-02-10 Univ New South Wales Kensingto Serumfreies gewebekulturmedium, das ein polymerzellenschutzmittel enthält.
US5045468A (en) 1986-12-12 1991-09-03 Cell Enterprises, Inc. Protein-free culture medium which promotes hybridoma growth
JPH01503679A (ja) 1987-06-30 1989-12-14 アムジエン・インコーポレーテツド カリクレインの生産
JP2507882B2 (ja) 1988-02-17 1996-06-19 工業技術院長 外部増殖因子非依存性増殖良好細胞株の製造法
US6048728A (en) * 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
US5573937A (en) * 1989-12-07 1996-11-12 Snow Brand Milk Products Co., Ltd. Serum free culture medium
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
ATE145235T1 (de) 1990-01-22 1996-11-15 Us Health Co-unabhängiges nährmedium zur haltung und vermehrung von zellen
JP2844484B2 (ja) 1990-02-22 1999-01-06 味の素株式会社 組換え蛋白質の生産方法
JP2859679B2 (ja) 1990-03-01 1999-02-17 協和醗酵工業株式会社 新規細胞株
US5378612A (en) * 1990-05-11 1995-01-03 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Culture medium for production of recombinant protein
JP2696001B2 (ja) 1991-04-15 1998-01-14 財団法人化学及血清療法研究所 組換え蛋白質産生用培地
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9022545D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Culture medium
CA2053433C (en) 1990-10-19 1997-03-25 Michael Joseph Garvey Detergent compositions
JPH04228066A (ja) 1990-10-23 1992-08-18 Rikagaku Kenkyusho 外来遺伝子発現用培養細胞
EP0531562A1 (de) * 1991-09-11 1993-03-17 Doerr, Hans-Wilhelm, Prof. Dr. med. Kultivierung von Säugetierzellen
CA2078721A1 (en) 1991-09-24 1993-03-25 Hiroshi Yonemura Process for preparing human coagulation factor viii protein complex
JPH05123178A (ja) 1991-11-01 1993-05-21 Ajinomoto Co Inc Ｌ−フエニルアラニンの製造法
DE4313620A1 (de) 1993-04-26 1994-10-27 Biotechnolog Forschung Gmbh Hamsterzellinien und Verfahren zur Glykoproteingewinnung
AU7895898A (en) 1993-04-26 1998-10-08 Hans Wolf Mammal cell lines and method of obtaining glycoproteins
GB9311132D0 (en) * 1993-05-28 1993-07-14 Eisai London Res Lab Ltd Control of cell death
US5405637A (en) 1993-06-30 1995-04-11 Bristol-Myers Squibb Company Milk protein partial hydrolysate and infant formula containing same
JP2766165B2 (ja) 1993-08-02 1998-06-18 株式会社バイオポリマー・リサーチ バクテリアセルロースの製造方法
US5445956A (en) * 1993-08-13 1995-08-29 The Regents Of The University Of California Recombinant soluble epoxide hydrolase
EP0653487A1 (de) 1993-11-07 1995-05-17 Ferruccio Dr. Messi Serum- und proteinfrei wachsende Zellen
US5719050A (en) * 1993-12-24 1998-02-17 Eiken Chemical Co., Ltd. Animal cell culturing media containing N-acetyl-L-glutamic acid
US5498599A (en) * 1994-01-21 1996-03-12 Amgen Inc. Methods for stimulating platelet production
EP0666312A1 (en) 1994-02-08 1995-08-09 Wolfgang A. Renner Process for the improvement of mammalian cell growth
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5789247A (en) * 1994-04-01 1998-08-04 Ballay; Annick Expression in non-tumoral human lymphoblastoid lines with an integrative vector
EP0733100A1 (de) 1994-09-09 1996-09-25 Wolfgang A. Renner Chemisches verfahren zur förderung der proliferation von tierischen zellen
ATE542891T1 (de) 1994-11-10 2012-02-15 Baxter Healthcare Sa Verfahren zur herstellung von biologischen produkten in protein-freier kultur
AT403167B (de) 1994-11-14 1997-11-25 Immuno Ag Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems
WO1996018734A1 (en) 1994-12-16 1996-06-20 Novartis Ag Production of recombinant secretory component
US5741705A (en) * 1995-02-23 1998-04-21 Quest International Flavors & Food Ingredients Company, Division Of Indopco, Inc. Method for in vitro cell growth of eucaryotic cells using low molecular weight peptides
CA2211630A1 (en) 1995-02-23 1996-08-29 Quest International B.V. Peptides for tissue and cell culture media
AU6125396A (en) 1995-06-07 1996-12-30 Novartis Ag Serum-free media for primitive hematopoietic cells and metho ds of use thereof
AUPN442295A0 (en) 1995-07-26 1995-08-17 Commonwealth Scientific And Industrial Research Organisation Regulated autocrine growth of mammalian cells
US5851800A (en) * 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
AU4081997A (en) 1996-08-30 1998-03-19 University Of North Carolina At Chapel Hill, The Immortalized human hepatic cell line
EP1482031B1 (en) 1996-08-30 2015-10-28 Life Technologies Corporation Serum-free mammalian cell culture medium, and uses thereof
EP0954563B1 (en) 1996-10-10 2008-07-02 Invitrogen Corporation Animal cell culture media comprising plant-derived nutrients
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
EP1849860B1 (en) 1997-05-28 2010-11-17 Novartis Vaccines and Diagnostics S.r.l. Process for preparing an immunogenic factor of Corynebacterium diphtheriae using a culture medium with yeast extract as aminoacid source and no protein complexes of animal origin
AT407255B (de) * 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
US6475725B1 (en) * 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
AU754619B2 (en) 1997-07-23 2002-11-21 Roche Diagnostics Gmbh Production of erythropoietin by endogenous gene activation
NZ505099A (en) 1997-11-20 2002-03-01 Weyerhaeuser Co Nutritive media and manufactured seeds comprising same
EP1045898A2 (en) * 1998-01-12 2000-10-25 Betagene, Inc. Compositions and methods for regulated secretion from neuroendocrine cell lines
FR2775983B1 (fr) 1998-03-13 2000-11-10 Pasteur Merieux Serums Vacc Milieu et procede de propagation et de multiplication virales
WO1999057246A1 (en) 1998-05-01 1999-11-11 Life Technologies, Inc. Animal cell culture media comprising non-animal or plant-derived nutrients
US6537782B1 (en) * 1998-06-01 2003-03-25 Chugai Seiyaku Kabushiki Kaisha Media for culturing animal cells and process for producing protein by using the same
US6406909B1 (en) 1998-07-10 2002-06-18 Chugai Seiyaku Kabushiki Kaisha Serum-free medium for culturing animal cells
JP4266055B2 (ja) 1999-03-04 2009-05-20 雪印乳業株式会社 ポリアミン組成物の製造法
AT409379B (de) * 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
EP1200561B1 (de) 1999-08-05 2006-06-14 Baxter Aktiengesellschaft Rekombinanter stabiler zellklon, seine herstellung und verwendung
AU784506B2 (en) 1999-08-25 2006-04-13 Immunex Corporation Compositions and methods for improved cell culture
US6596526B1 (en) * 2000-06-09 2003-07-22 Baxter Aktiengesellschaft Furin polypeptides with improved characteristics
KR100927517B1 (ko) 2000-09-25 2009-11-17 폴리문 사이언티픽 임무노이비오로기쉐 포르슝 게엠베하 생균 백신
EP1208966A1 (en) 2000-11-27 2002-05-29 Cheng-Kun Liao Manufacturing process of patio tabletop glass with broken protection
DE10059175A1 (de) 2000-11-29 2002-06-20 Siemens Ag Verfahren und Vorrichtung zur Anrufumleitung mittels eines Stellvertreters in einem Kommunikationssystem
US20030096414A1 (en) 2001-03-27 2003-05-22 Invitrogen Corporation Culture medium for cell growth and transfection
US6734289B2 (en) * 2001-03-29 2004-05-11 The University Of Chicago Gastrokines and derived peptides including inhibitors
AU2002316230A1 (en) 2001-06-13 2002-12-23 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
US7037658B2 (en) * 2001-08-16 2006-05-02 Regents Of University Of Michigan Methods and compositions for detecting variant ADAMTS13 genes
CA2460206C (en) 2001-10-02 2012-01-24 Novo Nordisk Health Care Ag Method for production of recombinant proteins in eukaryote cells
US20030104527A1 (en) * 2001-12-03 2003-06-05 National Research Council Of Canada Methylotrophic bacterium for the production of recombinant proteins and other products
DE10161412A1 (de) * 2001-12-13 2003-07-03 Aventis Pharma Gmbh Verfahren zur Bestimmung der Aktivität der Ornithin-Decarboxylase sowie zur Identifizierung von Effektoren der Ornithin-Decarboxylase-Aktivität
CA2491992A1 (en) 2002-07-09 2004-01-15 Baxter International, Inc. Animal protein free media for cultivation of cells
FR2846005B1 (fr) 2002-10-16 2006-06-23 Maco Pharma Sa Composition pour milieu biologique comprenant de l'erythorbate de sodium
FR2846004B1 (fr) 2002-10-16 2006-06-23 Maco Pharma Sa Composition pour culture de cellules notamment animales ou de tissus, comprenant du polyethylene glycol
DE10333675A1 (de) 2003-07-24 2005-03-03 Aventis Pharma Deutschland Gmbh Perfusionsverfahren für die Produktion von Erythropoietin
WO2005035748A1 (en) 2003-10-10 2005-04-21 Novo Nordisk Health Care Ag Method for large-scale production of a polypeptide in eukaryote cells and a culture vessel suitable therefor
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
WO2006050050A2 (en) 2004-10-29 2006-05-11 Centocor, Inc. Chemically defined media compositions
RU2486236C2 (ru) 2006-01-04 2013-06-27 Бакстер Интернэшнл Инк. Способ экспрессии белка

Also Published As

Publication number Publication date
DK1974014T3 (en) 2017-06-19
US20160068587A1 (en) 2016-03-10
US20110151512A1 (en) 2011-06-23
LT1974014T (lt) 2017-11-27
WO2007077217A2 (en) 2007-07-12
ES2790887T3 (es) 2020-10-29
KR101423344B1 (ko) 2014-07-30
US10696731B2 (en) 2020-06-30
EP1974014A2 (en) 2008-10-01
EP3653699A1 (en) 2020-05-20
RU2486236C2 (ru) 2013-06-27
RU2642269C9 (ru) 2018-10-31
RU2758802C2 (ru) 2021-11-02
SI2522717T1 (sl) 2014-05-30
JP2013106616A (ja) 2013-06-06
CY1119046T1 (el) 2018-01-10
HK1177950A1 (en) 2013-08-30
JP7134157B2 (ja) 2022-09-09
EP1974014B1 (en) 2017-04-19
JP6567490B2 (ja) 2019-08-28
US20070212770A1 (en) 2007-09-13
JP2015006209A (ja) 2015-01-15
RU2008131953A (ru) 2010-02-10
ES2629304T3 (es) 2017-08-08
US9758568B2 (en) 2017-09-12
RU2013112019A (ru) 2014-09-27
US20170362300A1 (en) 2017-12-21
CN101360820A (zh) 2009-02-04
KR101422435B1 (ko) 2014-07-22
DK2522717T3 (da) 2014-04-22
EP3121266B1 (en) 2020-02-26
DK3121266T3 (da) 2020-05-11
AU2007204044B2 (en) 2012-09-27
PL1974014T3 (pl) 2017-09-29
PL3121266T3 (pl) 2020-07-13
RU2017144220A3 (pt) 2021-03-01
PL2522717T3 (pl) 2014-08-29
CN102643777A (zh) 2012-08-22
EP2522717A1 (en) 2012-11-14
JP5259418B2 (ja) 2013-08-07
JP2018075032A (ja) 2018-05-17
PT1974014T (pt) 2017-05-26
WO2007077217A3 (en) 2007-11-08
KR20080083197A (ko) 2008-09-16
KR20130100224A (ko) 2013-09-09
CA2633306A1 (en) 2007-07-12
RU2017144220A (ru) 2019-06-18
PT2522717E (pt) 2014-05-15
EP3121266B8 (en) 2020-04-22
JP2017055770A (ja) 2017-03-23
RU2642269C2 (ru) 2018-01-24
ES2474573T3 (es) 2014-07-09
EP2522717B1 (en) 2014-04-02
JP2009521941A (ja) 2009-06-11
HUE032744T2 (en) 2017-10-30
JP2020028307A (ja) 2020-02-27
AU2007204044A1 (en) 2007-07-12
EP3121266A1 (en) 2017-01-25

Similar Documents

Publication Publication Date Title
HK1177950A1 (en) Oligopeptide-free cell culture media
HK1246827A1 (zh) 細胞培養方法
GB0613756D0 (en) Cell culture medium
IL197444A0 (en) Cell culture improvements
IL198486A0 (en) Rationally designed media for cell culture
GB0623635D0 (en) Pluripotent cell growth media
EP1997877A4 (en) CELL CULTURE SUBSTRATE
EP2028264A4 (en) CELL INCUBATOR
EP1988804A4 (en) MICRO FLUID CELL CULTURE MEDIA
GB0517382D0 (en) Cell culture
GB2435475B (en) Selective culture medium
GB0610009D0 (en) Culture medium
IL194524A0 (en) Three dimensional cell culture
GB0606671D0 (en) Cell Culture
ZA200905287B (en) A medium for a cell culture
AU2007903919A0 (en) Cell culture media
AU2006901495A0 (en) Cell culture